USRE47222EActiveUtility

Peptide sequences and compositions

63
Assignee: PEPTCELL LTDPriority: Sep 13, 2007Filed: Sep 5, 2008Granted: Feb 5, 2019
Est. expirySep 13, 2027(~1.2 yrs left)· nominal 20-yr term from priority
Inventors:Gregory Alan StoloffWilson Romero Caparros-Wanderley
A61P 43/00A61P 33/02A61P 33/00A61P 33/14A61P 31/12A61P 31/04A61P 33/06A61P 33/10A61K 2039/53A61K 38/00Y10S530/806Y10S530/855C07K 14/43577A61K 39/005Y10S530/858Y02A50/30
63
PatentIndex Score
0
Cited by
22
References
50
Claims

Abstract

Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A polypeptide composition comprising an one or more isolated polypeptide polypeptides and a carrier, the one or more isolated polypeptide being polypeptides including a polypeptide of SEQ ID NO: 35 or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 35, wherein the isolated polypeptide elicits an immune response in vertebrates against at least one epitope of a protein from an arthropod saliva fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDa or less polypeptide composition elicits an immune response in vertebrates against a protein comprising SEQ ID NO: 35. 
     
     
       2. The polypeptide composition according to  claim 1 , wherein the composition further comprises one or more further isolated polypeptides, the one or more further isolated polypeptides being one or more isolated polypeptides further comprise a polypeptide of SEQ ID NO: 6, SEQ ID NO: 20, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32, or a polypeptide with a sequence having 85% homology or more to SEQ ID NO:6, SEQ ID NO: 20, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32. 
     
     
       3. The polypeptide composition according to  claim 1 , which composition comprises 2 or more isolated polypeptides. 
     
     
       4. The polypeptide composition according to  claim 1 , wherein the protein from the arthropod saliva fraction has a mass from 20 kDa to 40 kDa, or has a mass of 20 kDa or less. 
     
     
       5. The polypeptide composition according to  claim 1 , wherein the isolated polypeptide includes a cytotoxic T lymphocyte (CTL) epitope, and/or the isolated polypeptide includes a T helper lymphocyte (Th) epitope, and/or the isolated polypeptide includes a B lymphocyte epitope. 
     
     
       6. The polypeptide composition according to  claim 1 , comprising 2, 3, 4, 5, 6 or more epitopes. 
     
     
       7. The polypeptide composition according to  claim 1 , which is immunogenic against a plurality of arthropod salivary proteins. 
     
     
       8. The polypeptide composition according to  claim 1 , wherein the arthropod saliva protein fraction is a mosquito saliva protein fraction from any mosquito species. 
     
     
       9. The polypeptide composition according to  claim 1 , further comprising one or more further sequences from an arthropod salivary protein. 
     
     
       10. The polypeptide composition according to  claim 2 , in which wherein the one or more further isolated polypeptides present are further comprise:
 a) SEQ ID NO: 20, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32; 
 b) SEQ ID NO: 20, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO: 32; 
 c) SEQ ID NO: 91, SEQ ID NO: 115 or SEQ ID NO: 116; 
 d) SEQ ID NO: 91, SEQ ID NO: 115 and SEQ ID NO: 116; 
 e) SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117; 
 f) SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117; 
 g) SEQ ID NO: 91, SEQ ID NO: 105, SEQ ID NO: 115, or SEQ ID NO: 116; or 
 h) SEQ ID NO: 91, SEQ ID NO: 105, SEQ ID NO: 115, and SEQ ID NO: 116. 
 
     
     
       11. The polypeptide composition of  claim 1 , further comprising a pharmaceutically acceptable carrier. 
     
     
       12. A method of producing a polypeptide composition of  claim 1 , which method comprises mixing or combining one or more of the polypeptides with one or more further polypeptides, and/or with one or more further components, such as a carrier, an excipient, an adjuvant, a buffer, or a stabiliser. 
     
     
       13. A polypeptide construct comprising an isolated polypeptide according to claim 1 linked to a carrier, the isolated polypeptide being SEQ ID NO: 35 or a sequence having 85% homology or more to SEQ ID NO 35, wherein the isolated polypeptide elicits an immune response in vertebrates against at least one epitope of a protein from an arthropod saliva fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDa or less. 
     
     
       14. A method of producing a polypeptide construct as defined in  claim 13 , which method comprises attaching, combining or mixing a polypeptide composition with the carrier. 
     
     
       15. The polypeptide construct according to  claim 13 , wherein the carrier comprises an adjuvant and/or an excipient. 
     
     
       16. The polypeptide composition according to  claim 2 , wherein the one or more further isolated polypeptides include a polypeptide having 85% homology or more to SEQ ID NO:6, a polypeptide having 85% homology or more to SEQ ID NO: 20, a polypeptide having 85% homology or more to SEQ ID NO: 28, a polypeptide having 85% homology or more to SEQ ID NO: 30, a polypeptide having 85% homology or more to SEQ ID NO: 31, or a polypeptide having 85% homology or more to SEQ ID NO: 32, SEQ ID NO: 91, SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116 and/or SEQ ID NO: 117. 
     
     
       17. The polypeptide composition according to  claim 3 , which composition comprises from 2 to 12 isolated polypeptides. 
     
     
       18. The polypeptide composition according to claim  3  1, which composition comprises from 2-6 isolated polypeptides wherein the one or more isolated polypeptides includes a polypeptide having 85% homology or more to SEQ ID NO: 35 or SEQ ID NO: 120. 
     
     
       19. The polypeptide composition according to claim  8  2, wherein the mosquito species is Anopheles gambiae one or more isolated polypeptides further comprise:
 a) SEQ ID NO: 91, SEQ ID NO: 115, SEQ ID NO: 116 or SEQ ID NO: 120; 
 b) SEQ ID NO: 91, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 120; 
 c) SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 or SEQ ID NO: 120; 
 d) SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 and SEQ ID NO: 120; 
 e) SEQ ID NO: 91, SEQ ID NO: 105, SEQ ID NO: 115, SEQ ID NO: 116 or SEQ ID NO: 120; or 
 f) SEQ ID NO: 91, SEQ ID NO: 105, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 120. 
 
     
     
       20. The polypeptide construct according to claim 1, wherein the carrier comprises an adjuvant and/or an excipient. 
     
     
       21. A polypeptide composition comprising one or more isolated polypeptides and a carrier, the one or more isolated polypeptides including a polypeptide of SEQ ID NO: 91 or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 91, wherein the polypeptide composition elicits an immune response in vertebrates against a protein comprising SEQ ID NO: 91. 
     
     
       22. The polypeptide composition according to claim 21, wherein the sequence having 85% homology or more to SEQ ID NO: 91 is SEQ ID NO: 6. 
     
     
       23. The polypeptide composition according to claim 21, wherein the one or more isolated polypeptides further comprise a polypeptide of SEQ ID NO: 115, SEQ ID NO: 116 or SEQ ID NO: 120, or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 115, SEQ ID NO: 116 or SEQ ID NO: 120. 
     
     
       24. The polypeptide composition according to claim 21, wherein the carrier comprises an adjuvant and/or an excipient. 
     
     
       25. The polypeptide composition according to claim 23, comprising SEQ ID NO: 91, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 120. 
     
     
       26. The polypeptide composition according to claim 23, comprising a polypeptide having 85% homology or more to SEQ ID NO: 91, a polypeptide having 85% homology or more to SEQ ID NO: 115, a polypeptide having 85% homology or more to SEQ ID NO: 116 and a polypeptide having 85% homology or more to SEQ ID NO: 120. 
     
     
       27. The polypeptide construct comprising an isolated polypeptide according to claim 21 linked to a carrier. 
     
     
       28. A polypeptide composition comprising one or more isolated polypeptides and a carrier, the one or more isolated polypeptides including SEQ ID NO: 115 or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 115, wherein the polypeptide composition elicits an immune response in vertebrates against a protein comprising SEQ ID NO: 115. 
     
     
       29. The polypeptide composition according to claim 28, wherein the sequence having 85% homology or more to SEQ ID NO: 115 is SEQ ID NO: 30. 
     
     
       30. The polypeptide composition according to claim 28, wherein the one or more isolated polypeptides further comprise a polypeptide of SEQ ID NO: 91, SEQ ID NO: 116 or SEQ ID NO: 120, or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 91, SEQ ID NO: 116 or SEQ ID NO: 120. 
     
     
       31. The polypeptide construct according to claim 28, wherein the carrier comprises an adjuvant and/or an excipient. 
     
     
       32. The polypeptide composition according to claim 30, wherein the one or more isolated polypeptides present are SEQ ID NO: 91, SEQ ID NO: 116 and SEQ ID NO: 120. 
     
     
       33. The polypeptide composition according to claim 30, wherein the one or more isolated polypeptides include a polypeptide having 85% homology or more to SEQ ID NO: 91, a polypeptide having 85% homology or more to SEQ ID NO: 116 and a polypeptide having 85% homology or more to SEQ ID NO: 120. 
     
     
       34. The polypeptide composition comprising an isolated polypeptide according to claim 28 linked to a carrier. 
     
     
       35. A polypeptide composition comprising one or more isolated polypeptides and a carrier, the one or more isolated polypeptides including a polypeptide of SEQ ID NO: 116 or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 116, wherein the polypeptide composition elicits an immune response in vertebrates against a protein comprising SEQ ID NO: 116. 
     
     
       36. The polypeptide composition according to claim 35, wherein the sequence having 85% homology or more to SEQ ID NO: 116 is SEQ ID NO: 31. 
     
     
       37. The polypeptide composition according to claim 35, wherein the one or more isolated polypeptides further comprise a polypeptide of SEQ ID NO: 91, SEQ ID NO: 115 or SEQ ID NO: 120, or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 91, SEQ ID NO: 115 or SEQ ID NO: 120. 
     
     
       38. The polypeptide construct according to claim 35, wherein the carrier comprises an adjuvant and/or an excipient. 
     
     
       39. The polypeptide composition according to claim 37, in which the one or more isolated polypeptides present are SEQ ID NO: 91, SEQ ID NO: 115 and SEQ ID NO: 120. 
     
     
       40. The polypeptide composition according to claim 37, wherein the one or more isolated polypeptides include a polypeptide having 85% homology or more to SEQ ID NO: 91, a polypeptide having 85% homology or more to SEQ ID NO: 115 and a polypeptide having 85% homology or more to SEQ ID NO: 120. 
     
     
       41. The polypeptide construct comprising an isolated polypeptide according to claim 35 linked to a carrier. 
     
     
       42. A polypeptide composition comprising one or more isolated polypeptides and a carrier, the one or more isolated polypeptides including a polypeptide of SEQ ID NO: 120 or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 120, wherein the polypeptide composition elicits an immune response in vertebrates against a protein comprising SEQ ID NO: 120. 
     
     
       43. The polypeptide composition according to claim 42, wherein the sequence having 85% homology or more to SEQ ID NO: 120 is SEQ ID NO: 35. 
     
     
       44. The polypeptide composition according to claim 42, wherein the one or more isolated polypeptides further comprise a polypeptide of SEQ ID NO: 91, SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116 or SEQ ID NO: 117, or a polypeptide with a sequence having 85% homology or more to SEQ ID NO: 91, SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116 or SEQ ID NO: 117. 
     
     
       45. The polypeptide construct according to claim 42, wherein the carrier comprises an adjuvant and/or an excipient. 
     
     
       46. The polypeptide composition according to claim 43, in which the one or more isolated polypeptides present are SEQ ID NO: 91, SEQ ID NO: 115 and SEQ ID NO: 116. 
     
     
       47. The polypeptide composition according to claim 43, in which the one or more isolated polypeptides present are SEQ ID NO: 105, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117. 
     
     
       48. The polypeptide composition according to claim 43, wherein the one or more isolated polypeptides include a polypeptide having 85% homology or more to SEQ ID NO: 91, a polypeptide having 85% homology or more to SEQ ID NO: 115 and a polypeptide having 85% homology or more to SEQ ID NO: 116. 
     
     
       49. The polypeptide composition according to claim 43, wherein the one or more isolated polypeptides include a polypeptide having 85% homology or more to SEQ ID NO: 105, a polypeptide having 85% homology or more to SEQ ID NO: 113, a polypeptide having 85% homology or more to SEQ ID NO: 115, a polypeptide having 85% homology or more to SEQ ID NO: 116 and a polypeptide having 85% homology or more to SEQ ID NO: 117. 
     
     
       50. The polypeptide construct comprising an isolated polypeptide according to claim 42 linked to a carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.